Skip to main content

Table 2 Clinical and biochemical characteristics at baseline and after supplementation1,2

From: Effect of a fat spread enriched with medium-chain triacylglycerols and a special fatty acid-micronutrient combination on cardiometabolic risk factors in overweight patients with diabetes

  MCT intake > 7 g/d (n = 21) MCT intake ≤ 7 g/d (n = 22) Pb
  wk 0 wk 12 wk 12 - 0 P a wk 0 wk12 wk 12 - 0 P a  
Age (years) 67.3 ± 9.3     66.3 ± 7.2     0.512
Weight (kg) 95.7 ± 21.2 95.3 ± 21.7 -0.35 ± 1.92 0.641 87.7 ± 11.6 88.3 ± 11.7 0.54 ± 1.76 0.118 0.177
BMI (kg/m2) 34.35 ± 6.84 34.23 ± 7.08 -0.12 ± 0.70 0.681 31.69 ± 4.05 31.89 ± 4.10 0.20 ± 0.61 0.092 0.174
WC (cm) 112.5 ± 12.5 110.7 ± 12.9 -1.81 ± 2.69 0.005 106.4 ± 6.6 106.7 ± 7.0 0.32 ± 3.03 1.000 0.027
WHtR 0.676 ± 0.076 0.665 ± 0.079 -0.010 ± 0.016 0.008 0.640 ± 0.045 0.642 ± 0.049 0.002 ± 0.018 0.920 0.018
SBP (mmHg) 138.6 ± 18.4 137.9 ± 12.0 -0.7 ± 13.2 0.792 148.4 ± 18.6 142.0 ± 17.2 -6.4 ± 15.4 0.069 0.249
DBP (mmHg) 84.8 ± 11.7 84.1 ± 7.7 -0.7 ± 10.3 0.707 87.7 ± 8.7 85.2 ± 8.7 -2.5 ± 9.2 0.170 0.612
Fasting TG (mg/dl) 147.3 ± 92.0 181.6 ± 122.7 34.2 ± 72.6 0.021 166.5 ± 113.3 216.6 ± 177.1 50.1 ± 108.1 0.022 0.990
TC (mg/dl) 209.5 ± 41.0 214.0 ± 41.6 4.52 ± 18.60 0.177 217.7 ± 37.9 225.4 ± 42.7 7.68 ± 23.04 0.058 0.527
LDL-C (mg/dl) 128.8 ± 34.9 130.7 ± 32.3 1.95 ± 16.59 0.357 136.4 ± 34.9 135.6 ± 40.1 -0.86 ± 22.04 0.848 0.618
HDL-C (mg/dl) 52.1 ± 10.8 49.7 ± 10.6 -2.39 ± 8.75 0.230 49.5 ± 9.9 51.4 ± 13.9 1.88 ± 6.71 0.363 0.085
TC/HDL-C 4.15 ± 0.98 4.50 ± 1.37 0.35 ± 0.82 0.064 4.51 ± 1.01 4.65 ± 1.50 0.14 ± 0.70 0.637 0.289
Non-HDL-C (mg/dl) 157.4 ± 40.3 164.3 ± 43.5 6.91 ± 18.8 0.058 168.2 ± 35.6 174.0 ± 42.8 5.80 ± 22.7 0.158 0.981
Fasting glucose (mg/dl) 127.5 ± 21.8 132.0 ± 29.7 4.48 ± 19.91 0.422 124.4 ± 23.9 126.5 ± 34.6 2.09 ± 18.70 0.676 0.313
Fasting insulin (μU/ml) 12.6 ± 9.1 13.7 ± 11.0 1.09 ± 9.33 0.509 14.4 ± 6.8 17.6 ± 25.4 3.17 ± 24.16 0.299 0.177
HOMA-Index 4.14 ± 3.73 4.81 ± 5.52 0.68 ± 5.21 0.639 4.46 ± 2.39 5.72 ± 9.01 1.26 ± 8.68 0.306 0.234
HbA1c (%) 6.76 ± 0.58 6.69 ± 0.78 -0.067 ± 0.380 0.367 6.46 ± 0.47 6.46 ± 0.53 0.004 ± 0.208 0.844 0.179
CRP (mg/l) 6.17 ± 5.97 5.52 ± 4.91 -0.66 ± 2.77 0.140 5.80 ± 8.46 4.45 ± 4.63 -1.35 ± 6.76 0.274 0.961
Uric acid (mg/l) 5.96 ± 1.53 6.27 ± 1.52 0.31 ± 0.66 0.024 6.58 ± 1.26 6.58 ± 1.04 0.00 ± 1.09 0.944 0.103
GGT (U/l) 43.8 ± 50.1 41.2 ± 26.4 -2.57 ± 27.84 0.265 43.8 ± 47.6 44.2 ± 30.5 0.45 ± 20.82 0.023 0.442
ASAT (U/l) 28.4 ± 10.6 28.0 ± 8.3 -0.43 ± 5.97 0.861 28.1 ± 11.9 27.1 ± 6.5 -1.00 ± 9.01 0.480 0.643
ALAT (U/l) 33.5 ± 21.8 31.2 ± 14.3 -2.24 ± 9.96 0.650 29.2 ± 14.1 30.4 ± 13.8 1.18 ± 10.77 0.166 0.607
GFR (mL/min/1.73 m2) 87.9 ± 19.1 86.4 ± 22.4 -1.54 ± 11.28 0.433 81.7 ± 15.7 83.4 ± 14.9 1.71 ± 8.60 0.095 0.290
U-Albumin (mg/24 h) 55.3 ± 199.4 19.5 ± 39.9 -35.8 ± 162.7 0.594 62.1 ± 225.8 60.0 ± 150.1 -2.1 ± 109.3 0.641 0.842
U-pH (24 h) 5.81 ± 0.81 5.52 ± 0.73 -0.29 ± 0.70 0.062 5.80 ± 1.08 6.05 ± 1.12 0.25 ± 0.88 0.176 0.032
U-Sodium (mmol/24 h) 212.0 ± 84.6 234.5 ± 89.0 22.5 ± 78.2 0.145 208.6 ± 67.6 231.0 ± 75.6 22.4 ± 72.2 0.153 1.000
  1. 1 data are presented as mean ± SD
  2. a p values for comparison between week 0 and 12 (Wilcoxon-Test)
  3. b p value for comparison of group × time interactions (Mann-Whitney-U-Test)
  4. 2 abbreviations used: ASAT, aspartate-aminotransferase; ALAT, alanine-aminotransferase; CRP, C reactive protein; DBP, diastolic blood pressure; GFR, glomerular filtration rate; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; MCT, medium-chain triacylglycerols; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHtR, waist to height ratio; U-albumin, urinary albumin; U-pH, urinary pH; U-sodium, urinary sodium